VIR · Vir Biotechnology, Inc.

The thesis

The response rate on the combined virus and liver-enzyme endpoint settles whether the shares, at $11.02 on 5 November 2026, go higher. As of 6 November 2026, Vir has published no ECLIPSE 1 result.

The date is the main change since the 29 October 2026 note. Vir said on 5 November 2026 that the primary-endpoint results will be a late-breaking oral presentation at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD) in Denver. Nancy Reau presents on 8 November 2026 at 2:15 p.m. Mountain Time, and Vir hosts an investor call on Monday, 9 November 2026, at 8:30 a.m. Eastern. Earlier guidance named only Q4 2026.

The 4 November 2026 third-quarter report left the plan unchanged. Vir reported a net loss of $96.3 million, or $0.57 per share, and $901.3 million in cash, cash equivalents and investments at 30 September 2026. That figure excludes $90 million from Gilead Sciences received in October, and runway guidance stays into the second half of 2028.

The narrative is accelerating: the 5 November 2026 notice turned a quarter-long window into a fixed date, and Needham raised its price target to $20 the same day, according to company news feeds.

Bullish and bearish views on Vir Biotechnology, Inc.

The bull case on Vir Biotechnology, Inc. (VIR), in brief: A fixed date removes timing risk. The bear case: The pivotal result remains binary.

Bull case

• A fixed date removes timing risk. Vir's 5 November 2026 release places the ECLIPSE 1 primary-endpoint results on the AASLD program for 8 November 2026. The prior concern that the readout could slip past Q4 2026 has largely fallen away.
• The comparison favors a statistical win. ECLIPSE 1 randomized about 120 untreated participants 2:1 to monthly elebsiran plus tobevibart or deferred treatment, CEO Marianne De Backer said on the 4 November 2026 call. ECLIPSE 3 carries the harder head-to-head test against bulevirtide, an existing hepatitis delta drug.
• Phase 2 response rates were high. In SOLSTICE, 66% of participants (21 of 32) reached and sustained undetectable virus at Week 48, per Vir's 2025 release, and 88% (28 of 32) had undetectable virus at Week 96, per company-reported EASL results on 30 May 2026. De Backer put bulevirtide at "somewhere between 12% and 20%" at 48 weeks on the 4 November 2026 call.
• The US market has no approved therapy. No chronic hepatitis delta therapy is approved by the FDA, and the ECLIPSE program is designed to supply the first. On the 4 November 2026 call, management described payer, diagnosis-tracking and distribution work, with no launch date given.
• Partner money funds the cancer platform. Gilead's terms are now disclosed: $90 million received, up to $45 million in near-term preclinical milestones, up to $1.74 billion in further milestones and tiered royalties, per the 4 November 2026 report and call. Astellas funds 60% of global VIR-5500 development, and multiple pivotal trials are expected to start in 2027.
• Most published targets sit above the price. Needham kept its Buy rating and set a $20 target on 5 November 2026, and HC Wainwright set $22 on 7 October 2026. Argus lowered its target to $11.00 on 16 September 2026.

Bear case

• The pivotal result remains binary. A primary-endpoint miss or a safety finding that blocks filing would break the hepatitis delta case. ECLIPSE 2 and 3 toplines are guided to Q1 2027, so a failure in the first trial would cloud both.
• The endpoint is stricter than the Phase 2 headlines. ECLIPSE 1 requires undetectable virus plus normal alanine aminotransferase (ALT), a liver enzyme, at Week 48, per the 4 November 2026 call. The 66% and 88% SOLSTICE figures count undetectable virus alone in 32 participants, so a headline rate under 66% could disappoint anyone anchored on them while still meeting the endpoint.
• Management set no public bar. On the 4 November 2026 call, De Backer gave no numeric threshold for ECLIPSE 1 and declined to say how much differentiation over bulevirtide ECLIPSE 3 needs. Morgan Stanley asked on the same call whether a competitor's Phase 3 results change the bar, so the regimen will be judged against rivals as well as its control arm.
• There is no product revenue behind the shares. Third-quarter total revenue was negative $0.2 million, and cash fell $106.5 million in the quarter, per the 4 November 2026 report. Weighted-average shares were 169,275,049, against 138,930,173 a year earlier.
• Cancer disclosures remain thin. Astellas said VIR-5500 reached proof of concept, but the criteria are undisclosed and De Backer declined to share updated durability results on the 4 November 2026 call. For VIR-5818, Vir is adding backfill cohorts to the monotherapy arm after FDA feedback.

Price setup

The adjusted close was $10.47 on 15 October 2026, $11.93 on 28 October 2026 and $11.02 on 5 November 2026, according to split- and dividend-adjusted daily closes. The 28 October 2026 close is the 52-week high, and the 5 November 2026 close sits 7.6% below it. The shares gave back part of the October gain before the results.

Crowding evidence is moderate. The shares rose 24.0% over three months, the 14-day relative strength index (RSI) was 60.5 on 5 November 2026, and the pivotal presentation falls three days after that close. Two negotiated share purchases frame the price: Astellas paid $10.36 in April 2026, and Gilead paid $14.16 in October 2026, a 30% premium by Vir's account.

Catalysts, next 30 days

• 8 November 2026, 2:15 p.m. Mountain Time: ECLIPSE 1 primary-endpoint results, late-breaking oral presentation at AASLD in Denver. This settles the first pivotal test.
• 8 November 2026: Expanded Phase 2 SOLSTICE results through Week 96, oral presentations at AASLD.
• 9 November 2026, 8:30 a.m. Eastern: Vir investor call on ECLIPSE 1 and SOLSTICE. Secondary endpoints, including the cirrhosis subgroup and safety, are the items to read, per the 4 November 2026 call.
• ~31 March 2027, est.: End of the guided Q1 2027 window for ECLIPSE 2 and 3 toplines and for a virtual research investor event. These results complete the intended global filing package.

What would change the view

A prespecified primary-endpoint miss in ECLIPSE 1 would break the case. So would a safety finding that blocks filing, or withdrawal of the 8 November 2026 presentation without results. A combined response rate well below SOLSTICE's Week 48 virus-only rate of 66%, paired with weak cirrhosis-subgroup results, would weaken the case for a differentiated drug even if the endpoint is met.

On price, a daily close below $10.30 would put the shares under the $10.36 Astellas paid in April 2026 and would end this reading. Positive ECLIPSE 2 and 3 toplines in Q1 2027 would strengthen the filing case; a miss in either would reopen it.

What it trades with

The next move depends on one company-specific clinical result, so the shares should respond more to the 8 November 2026 presentation than to index moves in the coming days. That view fails if the shares track broad biotech indexes through the release with no visible reaction to ECLIPSE 1.

Read-through runs in two directions. Competitor hepatitis delta results and bulevirtide's 12% to 20% rate, as cited by De Backer on 4 November 2026, frame how the ECLIPSE results are judged. VIR-5500 trial news from Astellas and any Gilead program milestone bear on the separate cancer platform.